Nimotuzumab with standard chemo-radiation for residual glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests adding nimotuzumab to the standard treatment (radiation and temozolomide chemotherapy) for people with glioblastoma that was not fully removed by surgery. It aims to see if this combination helps control the tumor better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with glioblastoma and your tumor shows a protein called EGFR.
- You had surgery that left some tumor behind, and it can be seen on scans.
- You are able to care for yourself (score of at least 50 on a standard scale).
- Your kidneys, liver, and blood counts are within acceptable levels.
- You have not had chemotherapy, radiation, or anti-EGFR treatment before, and no other cancer in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called nimotuzumab combined with radiation therapy for older adults (65+) with advanced head and neck cancer. It aims to help control the cancer when chemotherapy is not an option.
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests whether adding a special type of radiofrequency electromagnetic field treatment to standard chemotherapy and radiation therapy helps people with newly diagnosed glioblastoma. It is for patients who are planning to receive standard treatment and have had surgery to remove the tumor.
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.